Liberum Capital Lowers GlaxoSmithKline (LON:GSK) Price Target to GBX 1,840
GlaxoSmithKline (LON:GSK) had its price objective decreased by Liberum Capital from GBX 1,930 ($25.39) to GBX 1,840 ($24.20) in a research note released on Tuesday morning, Stock Target Advisor reports. Liberum Capital currently has a hold rating on the stock.
Several other analysts also recently issued reports on GSK. Morgan Stanley reissued a sell rating and issued a GBX 1,740 ($22.89) price target on shares of GlaxoSmithKline in a report on Tuesday, January 7th. Deutsche Bank set a GBX 1,600 ($21.05) price target on GlaxoSmithKline and gave the stock a neutral rating in a report on Monday, February 10th. DZ Bank raised their price target on GlaxoSmithKline from GBX 1,850 ($24.34) to GBX 2,000 ($26.31) and gave the stock a buy rating in a report on Thursday, October 31st. Shore Capital reissued a sell rating on shares of GlaxoSmithKline in a report on Wednesday, February 12th. Finally, Citigroup reissued a neutral rating on shares of GlaxoSmithKline in a report on Monday. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of GBX 1,846.87 ($24.29).
Shares of LON GSK opened at GBX 1,646.20 ($21.65) on Tuesday. The company has a market cap of $82.61 billion and a price-to-earnings ratio of 17.78. GlaxoSmithKline has a 12-month low of GBX 1,485.20 ($19.54) and a 12-month high of GBX 1,857 ($24.43). The company has a current ratio of 0.81, a quick ratio of 0.51 and a debt-to-equity ratio of 166.19. The stock’s 50 day simple moving average is GBX 1,769.45 and its 200 day simple moving average is GBX 1,726.12.
In other GlaxoSmithKline news, insider Judy Lewent bought 788 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were purchased at an average price of GBX 2,344 ($30.83) per share, with a total value of £18,470.72 ($24,297.18). Also, insider Emma Walmsley sold 11,680 shares of GlaxoSmithKline stock in a transaction on Monday, February 17th. The shares were sold at an average price of GBX 1,661 ($21.85), for a total value of £194,004.80 ($255,202.32). Insiders have acquired a total of 810 shares of company stock worth $1,885,602 in the last ninety days.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading: Do You Need a Fiduciary?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.